uniQure N.V.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 5 May 2026: press release. Guidance figures: 2 new, 3 kept. The quarter’s numbers.

Key takeaways

Net loss widened to $53.5 million: The company reported a net loss of $53.5 million, or $0.85 basic and diluted loss per ordinary share, compared with $43.6 million, or $0.82, a year earlier. Source
SG&A rose on commercial planning: SG&A was $20.1 million, against $10.9 million. The rise was mainly employee and contractor costs for staff recruited in 2025 to support AMT-130 commercial planning. Source
FDA will not accept external-control data: After the January 2026 Type A meeting, the FDA said it cannot agree that Phase I/II data compared with an external control are sufficient as primary evidence of effectiveness. Source
Progressing toward UK submission: After a constructive pre-submission meeting with the UK MHRA, the company is progressing AMT-130 toward its expected UK regulatory submission. Source
All 11 Fabry patients off ERT: As of February 18, 2026, all 11 dosed AMT-191 patients had been withdrawn from enzyme replacement therapy. Source
AMT-162 development discontinued after review: Following review of EPISOD1 data, the company discontinued AMT-162 development. Safety data continue to be collected from the five patients dosed in the trial. Source
Cash fell to $586.6 million: Cash, cash equivalents and current investment securities were $586.6 million at March 31, 2026, compared with $622.5 million at December 31, 2025. Source

“We believe our data continue to support the potential for AMT-130 to fundamentally change the treatment landscape for Huntington’s disease”
Matthew Kapusta, chief executive officer at uniQure

Guidance

Area	Period	Figure	Against last quarter
AMT-130 clinical data Source	third quarter of 2026	four-year AMT-130 data analysis	New
AMT-130 FDA interaction Source	second quarter of 2026	Type B meeting scheduled for the second quarter of 2026	Kept
AMT-260 clinical data Source	June 2026	first-cohort data, up to six months of follow-up, at June 18-19, 2026 conference	Kept
AMT-260 enrollment Source	mid-2026	second cohort enrollment completed in mid-2026	New
Cash runway Source	into the second half of 2029	into the second half of 2029	Kept

What changed from last quarter

New guidance: The company set a third-quarter 2026 target for an MAA submission to the UK MHRA, following a pre-submission meeting. Source
Ended: The company decided to discontinue development of AMT-162 after review of EPISOD1 data. Source
New: In April 2026, uniQure, CSL Behring and Genezen entered into agreements on HEMGENIX supply. Source
New: All 11 dosed AMT-191 patients had been withdrawn from enzyme replacement therapy by February 18, 2026, up from six in the prior release. Source
Guidance kept: Cash runway guidance into the second half of 2029 was restated. Source

Quarterly results and costs

Net loss widened to $53.5 million: The company reported a net loss of $53.5 million, or $0.85 basic and diluted loss per ordinary share, compared with $43.6 million, or $0.82, a year earlier. Source
Revenue rose on license income: Revenue was $3.6 million, compared with $1.6 million, and the company attributed the increase to higher license revenue. Source
R&D spend fell $6.9 million: R&D expenses were $29.2 million, against $36.1 million. Lower contingent consideration fair value, external program spend and employee costs drove the decrease. Source
SG&A rose on commercial planning: SG&A was $20.1 million, against $10.9 million. The rise was mainly employee and contractor costs for staff recruited in 2025 to support AMT-130 commercial planning. Source
Other income fell on reagent sale: Other income was $1.6 million, against $8.3 million, as the prior period included a one-time gain on the sale of critical reagents. Source
Currency losses lifted non-operating expense: Non-operating items, net, were an expense of $7.3 million, against $3.8 million, mainly from higher net foreign currency losses. Source

AMT-130 regulatory path

FDA will not accept external-control data: After the January 2026 Type A meeting, the FDA said it cannot agree that Phase I/II data compared with an external control are sufficient as primary evidence of effectiveness. Source
Type B meeting granted for Q2: The company has been granted a Type B meeting with the FDA to discuss a potential new trial design and to seek feedback on the statistical analysis plan for four-year data. Source
Progressing toward UK submission: After a constructive pre-submission meeting with the UK MHRA, the company is progressing AMT-130 toward its expected UK regulatory submission. Source

“following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter”
Matthew Kapusta, chief executive officer at uniQure

AMT-260 epilepsy program

Enrollment on track in epilepsy program: Management said enrollment in the AMT-260 temporal lobe epilepsy program is on track, with a first-cohort update to be presented at a conference. Source
First dose cohort completed in 2025: Enrollment in the first dose cohort of six patients in the Phase I/IIa study was completed during 2025. Source
Second dose cohort enrolling: Enrollment in a second dose cohort, expected to include an additional six patients, is ongoing. Source

Fabry and ALS programs

All 11 Fabry patients off ERT: As of February 18, 2026, all 11 dosed AMT-191 patients had been withdrawn from enzyme replacement therapy. Source
Enzyme activity increases remained durable: Dose-dependent increases in α-Gal A activity were durable across follow-up periods of four months to more than one year, while lyso-Gb3 levels stayed stable. Source
Fabry dosing paused over liver events: Additional dosing in the mid- and high-dose cohorts remains paused pending review of Grade 3 liver enzyme elevations, confirmed as dose-limiting toxicities. Source
AMT-162 development discontinued after review: Following review of EPISOD1 data, the company discontinued AMT-162 development. Safety data continue to be collected from the five patients dosed in the trial. Source

“With these important milestones ahead, we remain committed to advancing our programs with urgency while maintaining disciplined capital allocation to drive long-term shareholder value”
Matthew Kapusta, chief executive officer at uniQure

Cash and balance sheet

Cash fell to $586.6 million: Cash, cash equivalents and current investment securities were $586.6 million at March 31, 2026, compared with $622.5 million at December 31, 2025. Source
Runway into second half of 2029: Management expects cash, cash equivalents and investment securities to fund operations into the second half of 2029. Source
Warrant liability produced a gain: Non-operating items included a $3.8 million gain from changes in the fair value of the pre-funded warrant liability. Source

HEMGENIX supply agreements

HEMGENIX supply agreements signed: In April 2026, the company entered agreements with CSL Behring and Genezen that end its remaining HEMGENIX supply after mid-2026 batch delivery. Source
CSL now contracts directly with Genezen: CSL Behring entered a direct relationship with Genezen as the HEMGENIX supplier. The company said royalties and milestones are unaffected. Source
HEMGENIX supply costs fell: Other expense was $1.5 million, against $2.0 million, with a $0.3 million decrease in costs for supplying Hemgenix to CSL Behring. Source

Coming up, as management said on 5 May 2026

Type B meeting with FDA in Q2: The company plans to discuss key elements of a potential new clinical trial design at the FDA Type B meeting. Source
AMT-260 first-cohort data in June: First-cohort AMT-260 data are to be provided at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026. Source
Four-year AMT-130 data in Q3: Four-year AMT-130 data analysis is expected in the third quarter of 2026. Source
UK MAA submission in Q3: The company expects to submit an MAA for AMT-130 to the UK MHRA in the third quarter of 2026. Source
Second cohort enrollment completes mid-2026: Enrollment in the second AMT-260 cohort is expected to finish in mid-2026. Source
HEMGENIX supply ends mid-2026: Remaining HEMGENIX supply and minimum purchase commitments are expected to end after batch delivery in mid-2026. Source
RBC healthcare conference in May: Management plans to attend the 2026 RBC Capital Markets Global Healthcare Conference in New York. Source

Figures management reported

Figure	Reported
R&D expenses (three months ended March 31, 2026) Source	$29.2 million
AMT-191 patients withdrawn from ERT Source	11 of 11 dosed patients
AMT-260 first-cohort data timing Source	June 18-19, 2026 conference

Risks management discussed

Regulatory: The FDA said it cannot accept Phase I/II data compared with an external control as primary evidence of effectiveness for AMT-130. Source
Operational: Dosing in the Fabry mid- and high-dose cohorts is paused after Grade 3 liver enzyme elevations confirmed as dose-limiting toxicities. Source
Operational: AMT-162 development was discontinued after a serious adverse event determined to be a dose-limiting toxicity, following review of EPISOD1 data. Source
Financial: Non-operating items included higher net foreign currency losses, which increased non-operating expense by $3.5 million. Source

Earlier plans management reported on

On track: Management said the UK MAA is on track for the third quarter of 2026, following a pre-submission meeting with the MHRA. Source
On track: Management said enrollment in the AMT-260 epilepsy program is on track. Source
Not stated: The prior release said a Type B meeting would be requested in the second quarter of 2026; this release says the meeting has been granted. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company

Updates

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~

~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track for third quarter of 2026 following successful pre-submission meeting with UK MHRA~

~ Enrollment in AMT-260 temporal lobe epilepsy program on track; clinical update from first cohort in Phase I/IIa study to be presented at the Epilepsy Foundation Pipeline Conference ~

~ Presented updated data from AMT-191 Phase I/IIa in Fabry disease study showed sustained increases in α-Gal A Enzyme Activity and stable Lyso-Gb3 levels; subsequently all 11 dosed patients have discontinued enzyme replacement therapy ~

~ Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029 ~

~ uniQure to host earnings call at 8:30 a.m. ET ~

Lexington, MA and Amsterdam, the

Netherlands, May 5, 2026 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

“During the first quarter of 2026, we remained focused on advancing AMT-130 to patients globally as rapidly as possible while executing across our broader pipeline,” said Matthew Kapusta, chief executive officer at uniQure. “We believe our data continue to support the potential for AMT-130 to fundamentally change the treatment landscape for Huntington’s disease, and we look forward to continued engagement with the FDA. In parallel, following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter and evaluating additional international opportunities.”

“We expect to deliver key clinical updates throughout 2026, including data from our AMT-260 program in refractory mesial temporal lobe epilepsy later in the second quarter and four-year AMT-130 data analysis in the third quarter,” Mr. Kapusta continued. “With these important milestones ahead, we remain committed to advancing our programs with urgency while maintaining disciplined capital allocation to drive long-term shareholder value.”

Recent Company Developments and Updates

Advancing AMT-130 for the treatment of Huntington’s disease

The Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) in January 2026 to discuss the regulatory path forward following an October 2025 pre-Biologics License Application (BLA) meeting. Following receipt of final meeting minutes from the Type A meeting, the Company announced that the FDA stated it cannot agree that data from the Phase

I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130.

The Company has been granted a Type B meeting with the FDA and plans to discuss key elements of a potential new clinical trial design and to solicit feedback on the proposed statistical analysis plan for the four-year data expected in the third quarter of 2026.
Following a constructive pre-submission meeting with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA), the Company expects to submit a Marketing Authorization Application (MAA) for AMT-130 based on three-year data in the third quarter of 2026.

Continued clinical progress in pipeline programs

AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)

In 2025, the Company completed enrollment in the first dose cohort of six patients in the Phase I/IIa study. Enrollment is ongoing in a second dose cohort, expected to include an additional six patients. Enrollment of the second cohort is expected to be completed in mid-2026.
The Company expects to provide data from the first cohort of six patients in the Phase I/IIa study with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference, June 18 -19, 2026.

AMT-191 for the treatment of Fabry disease

In February 2026, the Company presented updated safety and exploratory efficacy data from the Phase I/II study of AMT-191 in Fabry disease (data cutoff as of January 8, 2026):
Dose-dependent elevations were observed across 11 patients in three dose levels with α-Gal A activity ranging from 0.34- to 82.2-fold above mean normal range at the lowest dose, 1.6- to 312.5-fold at the mid dose, and 27.7- to 223.7-fold at the highest dose. These increases were durable across follow-up periods ranging from four months to more than one year.
Plasma lyso-Gb3 levels were stable post-dose across all cohorts, regardless of enzyme replacement therapy (ERT) status.
As of February 18, 2026, all 11 dosed patients were withdrawn from ERT.
AMT-191 continued to show a manageable safety profile at all dose levels. No SAEs related to AMT-191 were observed at the 4x10 gc/kg and 2x10 gc/kg doses. No additional SAEs were observed at the 6x10 gc/kg dose beyond the five previously reported in September 2025 in two patients.
Per protocol, additional dosing in the mid- and high-dose cohorts has been paused pending further evaluation of asymptomatic Grade 3 liver enzyme elevations reported in two patients from the mid-dose cohort, which were confirmed as dose-limiting toxicities.

Normal range (1.38 - 8.66 nmol); mean normal of 3.57 nmol

AMT-162 for the treatment of SOD1 amyotrophic lateral sclerosis (ALS)

In 2025, the Company voluntarily paused enrollment in the Phase I/II EPISOD1 multi-center, open-label U.S. trial of AMT-162 for the treatment of SOD1-ALS, following an Independent Data Monitoring Committee review of available preliminary safety and efficacy data, including a SAE determined to be a dose-limiting toxicity observed in one patient in the second cohort. Following review of the preliminary efficacy and safety data generated from EPISOD1, the decision was made to discontinue development of AMT-162. Safety data will continue to be collected from the five patients dosed in EPISOD1, consistent with applicable safety and regulatory requirements.

Focused execution and strong financial position

In April 2026, uniQure, CSL Behring and Genezen entered into agreements under which uniQure’s remaining HEMGENIX® supply and any minimum purchase commitments will terminate after delivery of contractually specified batches to CSL Behring, which uniQure expects to occur in mid-2026. Concurrently, CSL Behring entered into a direct relationship with Genezen as the supplier of HEMGENIX®. These agreements have no impact on future royalties or milestones to uniQure under the license agreement with CSL Behring.
As of March 31, 2026, the Company had cash, cash equivalents and current investment securities of $586.6 million. The Company expects that cash, cash equivalents and investment securities will be sufficient to fund operations into the second half of 2029.

Financial Highlights

Cash Position: As of March 31, 2026, the Company held $586.6 million in cash, cash equivalents and current investment securities, compared to $622.5 million as of December 31, 2025. The Company expects that cash, cash equivalents and investment securities will be sufficient to fund operations into the second half of 2029.

Revenues: Revenue for the three months ended March 31, 2026 was $3.6 million, compared to $1.6 million in the same period in 2025. The increase of $2.0 million is due to an increase in license revenue, compared to the prior period.

R&D Expenses: Research and development expenses were $29.2 million for the three months ended March 31, 2026, compared to $36.1 million during the same period in 2025. The $6.9 million decrease was driven by a $2.6 million decrease in the fair value of contingent consideration, a $1.2 million decrease in costs related to external program spend, a $1.6 million decrease in employee and contractor-related expenses, including share-based compensation, and a $1.6 million decrease in facilities and other expenses, compared to the prior period.

SG&A Expenses: Selling, general and administrative expenses were $20.1 million for the three months ended March 31, 2026, compared to $10.9 million during the same period in 2025. The $9.2 million increase was primarily related to a $5.5 million increase in employee and contractor-related expenses, including share-based compensation, mainly as a result of employees recruited in 2025 to support commercial planning of AMT-130, a $1.8 million increase in professional fees, a $0.6 million increase in intellectual property fees, and a $1.3 million increase in information technology costs and other expenses, compared to the prior period.

Other Income: Other income was $1.6 million for the three months ended March 31, 2026, compared to $8.3 million during the comparative period in 2025. The $6.7 million decrease was primarily related to a prior period one-time gain of $6.0 million related to the sale of critical reagents and a $0.8 million decrease in research and development grants, compared to the prior period.

Other Expense: Other expense was $1.5 million for the three months ended March 31, 2026, compared to $2.0 million during the same period in 2025. The decrease was primarily due to a $0.3 million decrease in costs associated with the supply of Hemgenix® to CSL Behring and a $0.2 million decrease in sublease expenses in the three months ended March 31, 2026, compared to the prior period.

Other non-Operating Items, net: Other non-operating items, net was an expense of $7.3 million for the three months ended March 31, 2026, compared to an expense of $3.8 million for the same period in 2025. The $3.5 million increase was primarily related to an increase in net foreign currency losses of $9.5 million, offset by a $1.1 million increase in interest income, a $1.1 million decrease in interest expense, and a $3.8 million gain resulting from changes in the fair value of the liability related to pre-funded warrants, compared to the prior period.

Net loss: The net loss for the three months ending March 31, 2026, was $53.5 million, or $0.85 basic and diluted loss per ordinary share, compared to a $43.6 million net loss for the comparative period in 2025, or $0.82 basic and diluted loss per ordinary share.

Upcoming investor events:

2026 RBC Capital Markets Global Healthcare Conference, May 19th - New York, NY

Investor Conference Call and Webcast Information

uniQure management will host an investor conference call and webcast today, Tuesday, May 5th at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 4607289. If you are joining the conference call, please join 15 minutes before the start time.

About uniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B - an historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

Forward-looking statements notice

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “establish,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s cash runway and its ability to fund its operations into the second half of 2029; the Company’s ability and plans to strategically advance its programs; the Company’s plans and timing with respect to future interactions with regulatory authorities and regulatory updates related to AMT-130, including the Company’s plans to continue engaging with the FDA and have a Type B meeting regarding a potential new clinical trial design and statistical analysis plan for the four-year analysis of AMT-130, and the Company’s plans to submit a MAA to the MHRA in the third quarter of 2026; the potential for AMT-130 to change the treatment landscape for Huntington’s disease; the Company’s plans to enroll an additional six patients in a second cohort in the Phase I/IIa study for AMT-260 by mid-2026; the Company’s plans to provide further clinical updates, including plans to announce additional data from the Company’s AMT-260 program in June 2026 and four-year data from the Company’s AMT-130 program in the third quarter of 2026; the Company’s plans to continue to collect safety data from patients in the EPISOD1 trial of AMT-162; the timing of when the Company’s HEMGENIX® supply and minimum purchase commitments are expected to terminate pursuant to agreements entered into with CSL Behring and Genezen; and the Company’s plans to attend upcoming investor events. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks associated with the clinical results and the development and timing of the Company’s programs, including the risk that clinical results will be unable to demonstrate data sufficient to support further clinical development or regulatory approval in any country where approval is pursued; the risk that more patient data become available that results in a different interpretation than the one derived from preliminary, interim or topline data; the Company’s interactions with regulatory authorities, including the FDA and MHRA, which may affect the initiation, timing and progress of clinical trials and pathways and timing for regulatory approval; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression suitable for regulatory approval; the Company’s ability to conduct and fund a new study for AMT-130; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene therapies; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company’s ability to obtain, maintain and protect intellectual property; and the Company’s ability to fund its operations. These risks and uncertainties are more fully described under the heading “Risk Factors” in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

UNAUDITED CONSOLIDATED BALANCE SHEETS

	March 31,	December 31,
	2026	2025
	(in thousands, U.S. dollars)
Current assets
Cash and cash equivalents	$139,994	$80,240
Current investment securities	446,556	542,301
Accounts receivable	3,562	5,863
Prepaid expenses	16,589	20,506
Other current assets and receivables	9,043	7,076
Total current assets	615,744	655,986
Non-current assets
Property, plant and equipment, net	$12,014	$13,800
Other investments	30,150	30,237
Operating lease right-of-use assets	12,261	12,525
Intangible assets, net	69,990	72,790
Goodwill	24,811	25,355
Deferred tax assets, net	8,194	8,654
Other non-current assets	5,542	5,561
Total non-current assets	162,962	168,922
Total assets	$778,706	$824,908
Current liabilities
Accounts payable	$4,399	$5,170
Accrued expenses and other current liabilities	43,201	41,292
Liability related to pre-funded warrants	8,605	12,595
Current portion of operating lease liabilities	2,992	3,862
Total current liabilities	59,197	62,919
Non-current liabilities
Long-term debt	49,942	49,699
Liability from royalty financing agreement	482,334	473,199
Operating lease liabilities, net of current portion	10,388	9,832
Contingent consideration	17,029	18,736
Deferred tax liability, net	7,796	7,967
Other non-current liabilities, net of current portion	2,677	3,655
Total non-current liabilities	570,166	563,088
Total liabilities	629,363	626,007
Shareholders’ equity
Total shareholders’ equity	149,343	198,901
Total liabilities and shareholders’ equity	$778,706	$824,908

uniQure N.V.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended March 31,
	2026	2025
	(in thousands, U.S dollars, except share and per share amounts)
Total revenues	$3,562	$1,567
Operating expenses:
Cost of license revenues	(219)	(197)
Research and development expenses	(29,176)	(36,140)
Selling, general and administrative expenses	(20,068)	(10,908)
Total operating expenses	(49,463)	(47,245)
Other income	1,632	8,306
Other expense	(1,451)	(1,959)
Loss from operations	(45,720)	(39,331)
Non-operating items, net	(7,327)	(3,810)
Loss before income tax expense	$(53,047)	$(43,141)
Income tax expense	(488)	(496)
Net loss	$(53,535)	$(43,637)
Basic and diluted net loss per ordinary share	$(0.85)	$(0.82)
Weighted average shares used in computing basic and diluted net loss per ordinary share	62,742,847	53,110,580

Contacts
FOR INVESTORS: Chiara Russo · Direct: 781-491-4371 · Mobile: 617-306-9137 · c.russo@uniQure.com
FOR MEDIA: Tom Malone · Direct: 339-970-7558 · Mobile:339-223-8541 · t.malone@uniQure.com uniQure N.V.